BioXcel Therapeutics Inc (NASDAQ: BTAI) is -8.00% lower on its value in year-to-date trading and has touched a low of $0.30 and a high of $4.17 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BTAI stock was last observed hovering at around $0.35 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.34, the stock is -9.54% and -25.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.89 million and changing -0.52% at the moment leaves the stock -68.42% off its SMA200. BTAI registered -86.29% loss for a year compared to 6-month loss of -72.26%. The firm has a 50-day simple moving average (SMA 50) of $0.46192 and a 200-day simple moving average (SMA200) of $1.089465.
The stock witnessed a -15.35% gain in the last 1 month and extending the period to 3 months gives it a -40.69%, and is -8.83% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.96% over the week and 15.10% over the month.
BioXcel Therapeutics Inc (BTAI) has around 74 employees, a market worth around $17.07M and $2.28M in sales. Profit margin for the company is -3119.33%. Distance from 52-week low is 14.63% and -91.75% from its 52-week high. The company has generated returns on investments over the last 12 months (-374.29%).
with sales reaching $936.26k over the same period.The EPS is expected to grow by 72.28% this year, but quarterly earnings will post 136.11% year-over-year. Quarterly sales are estimated to grow 149.01% in year-over-year returns.
BioXcel Therapeutics Inc (BTAI) Top Institutional Holders
72.0 institutions hold shares in BioXcel Therapeutics Inc (BTAI), with institutional investors hold 10.96% of the company’s shares. The shares outstanding are 42.46M, and float is at 41.30M with Short Float at 1.96%. Institutions hold 8.76% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 2.99 million shares valued at $3.82 million. The investor’s holdings represent 9.6767% of the BTAI Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 2.21 million shares valued at $2.82 million to account for 7.1439 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.97 million shares representing 3.1438% and valued at over $1.24 million, while BLACKROCK INC. holds 1.4276 of the shares totaling 0.44 million with a market value of $0.56 million.
BioXcel Therapeutics Inc (BTAI) Insider Activity
The most recent transaction is an insider sale by O’Neill Vincent. SEC filings show that O’Neill Vincent sold 165 shares of the company’s common stock on Dec 16 ’24 at a price of $0.35 per share for a total of $58.0. Following the sale, the insider now owns 19957.0 shares.
BioXcel Therapeutics Inc disclosed in a document filed with the SEC on Dec 16 ’24 that Mehta Vimal (CEO and President) sold a total of 3,117 shares of the company’s common stock. The trade occurred on Dec 16 ’24 and was made at $0.36 per share for $1131.0. Following the transaction, the insider now directly holds 59605.0 shares of the BTAI stock.
Still, SEC filings show that on Dec 16 ’24, Steinhart Richard I (Chief Financial Officer) disposed off 577 shares at an average price of $0.36 for $207.0. The insider now directly holds 20,932 shares of BioXcel Therapeutics Inc (BTAI).
